# Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers

> **NCT02183649** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** pentoxyverine citrate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02183649
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183649, "Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*